{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:09Z","timestamp":1785250929200,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["S-000436 INFLUVAX"],"award-info":[{"award-number":["S-000436 INFLUVAX"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128728","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:59:00Z","timestamp":1779418740000},"page":"128728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Conjugate vaccine technology enhances responses to influenza virus"],"prefix":"10.1016","volume":"86","author":[{"given":"Lauren","family":"Myburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Koetsier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinty","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth J.M.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy R.","family":"van Beijnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan W.","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128728_bb0005","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2021.01.032","volume":"39","author":"Okoli","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128728_bb0010","series-title":"CDC Seasonal Flu Vaccine Effectiveness Studies","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128728_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2336357","article-title":"Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines","volume":"20","author":"Russell","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128728_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","article-title":"Challenges of making effective influenza vaccines","volume":"7","author":"Gouma","year":"2020","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.vaccine.2026.128728_bb0030","article-title":"Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines","volume":"10","author":"Trombetta","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128728_bb0035","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.vaccine.2018.01.045","article-title":"Influenza vaccine effectiveness in older adults compared with younger adults over five seasons","volume":"36","author":"Russell","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128728_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128728_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127281","article-title":"Guided design for the development of an evolution-proof influenza vaccine","volume":"59","author":"Myburgh","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128728_bb0050","series-title":"Advanced Vaccination Technologies for Infectious and Chronic Diseases","first-page":"51","author":"Apostolopoulos","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128728_bb0055","article-title":"Precision-engineering of subunit vaccine particles for prevention of infectious diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0060","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/21645515.2016.1276140","article-title":"The revival of cancer vaccines - the eminent need to activate humoral immunity","volume":"13","author":"Huijbers","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128728_bb0065","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2019.06.010","article-title":"Corrigendum to \u201cAn improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature\u201d [vaccine 36(21) 3054-3060]","volume":"37","author":"Huijbers","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128728_bb0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fimmu.2019.00651","article-title":"Targeting tumor vascular CD99 inhibits tumor growth","volume":"10","author":"Huijbers","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins\u202f: II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128728_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104719","article-title":"Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19","volume":"25","author":"Blanas","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2026.128728_bb0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.vaccine.2026.128728_bb0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.copbio.2006.06.003","article-title":"Enhancement of soluble protein expression through the use of fusion tags","volume":"17","author":"Esposito","year":"2006","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0095","doi-asserted-by":"crossref","first-page":"20248","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128728_bb0100","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03300","article-title":"The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin","volume":"3","author":"Thyagarajan","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2026.128728_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/v8060155","article-title":"Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin","volume":"8","author":"Doud","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128728_bb0110","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/cid\/ciz411","article-title":"Influenza vaccine effectiveness: defining the H3N2 problem","volume":"69","author":"Belongia","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128728_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003905","article-title":"Tailored immune responses: novel effector helper T cell subsets in protective immunity","volume":"10","author":"Kara","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128728_bb0120","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.4049\/jimmunol.1401031","article-title":"Dissecting the contribution of IgG subclasses in restricting airway infection with legionella pneumophila","volume":"193","author":"Weber","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0125","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2026.128728_bb0130","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1128\/JVI.01065-06","article-title":"Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza a viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines","volume":"80","author":"Wang","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/srep01822","article-title":"Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic","volume":"3","author":"Tharakaraman","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vaccine.2026.128728_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02649-23","article-title":"Comparative evolution of influenza a virus H1 and H3 head and stalk domains across host species","volume":"15","author":"Trov\u00e3o","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128728_bb0145","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","article-title":"Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy","volume":"13","author":"van Beijnum","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128728_bb0150","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1128\/IAI.67.8.4276-4279.1999","article-title":"Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization","volume":"67","author":"Barackman","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2026.128728_bb0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(96)00287-3","article-title":"Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza a subunit vaccine using various adjuvants","volume":"15","author":"Benne","year":"1997","journal-title":"Vaccine"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2026.128728_bb0160","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1099\/0022-1317-70-9-2439","article-title":"The immunoglobulin G subclass responses of mice to influenza a virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies","volume":"70","author":"Hocart","year":"1989","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128728_bb0165","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/infdis\/172.3.734","article-title":"Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity","volume":"172","author":"Tang","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128728_bb0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1084\/jem.165.1.64","article-title":"IgG2a restriction of murine antibodies elicited by viral infections","volume":"165","author":"Coutelier","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128728_bb0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/314952","article-title":"Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection","volume":"180","author":"Moran","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128728_bb0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/icb.2016.65","article-title":"IgG subclass co-expression brings harmony to the quartet model of murine IgG function","volume":"94","author":"Collins","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza a (H1N1) virus: from cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128728_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0200","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T cell response to respiratory virus infections","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126989","article-title":"Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine","volume":"54","author":"Myburgh","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128728_bb0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/erv.13.35","article-title":"Immunological assessment of influenza vaccines and immune correlates of protection","volume":"12","author":"Reber","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.128728_bb0215","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiu186","article-title":"Association between antibody titers and protection against influenza virus infection within households","volume":"210","author":"Tsang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128728_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02379-20","article-title":"A competitive Hemagglutination inhibition assay for dissecting functional antibody activity against influenza virus","volume":"95","author":"Kirchenbaum","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0225","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1038\/s41467-024-47590-0","article-title":"Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children","volume":"15","author":"Jia","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128728_bb0230","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","article-title":"Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128728_bb0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.antiviral.2013.09.018","article-title":"Universal anti-neuraminidase antibody inhibiting all influenza A subtypes","volume":"100","author":"Doyle","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.vaccine.2026.128728_bb0240","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1128\/JVI.01203-13","article-title":"Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses","volume":"87","author":"Wan","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0245","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1038\/ncomms7114","article-title":"Structural characterization of a protective epitope spanning a(H1N1)pdm09 influenza virus neuraminidase monomers","volume":"6","author":"Wan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128728_bb0250","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2016.10.001","article-title":"An influenza a virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo","volume":"135","author":"Wilson","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.vaccine.2026.128728_bb0255","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","article-title":"Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes","volume":"2","author":"Wohlbold","year":"2017","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/jcm.24.1.157-160.1986","article-title":"Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza a wild-type virus","volume":"24","author":"Clements","year":"1986","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128728_bb0270","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128728_bb0275","doi-asserted-by":"crossref","first-page":"20748","DOI":"10.1073\/pnas.1113801108","article-title":"Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses","volume":"108","author":"Sandbulte","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128728_bb0280","first-page":"67","article-title":"Neuraminidase-inhibition assay for the identification of influenza a virus neuraminidase subtype or neuraminidase antibody specificity","volume":"436","author":"Pedersen","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.vaccine.2026.128728_bb0285","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1099\/vir.0.043059-0","article-title":"Genetic evolution of the neuraminidase of influenza a (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution","volume":"93","author":"Westgeest","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128728_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153958","article-title":"Vaccination against extracellular vimentin for treatment of urothelial Cancer of the bladder in client-owned dogs","volume":"15","author":"Engbersen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2026.128728_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26189096","article-title":"Vaccination against extracellular vimentin plus doxorubicin for canine Hemangiosarcoma","volume":"26","author":"Engbersen","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vaccine.2026.128728_bb0300","series-title":"Key Facts About Seasonal Flu Vaccine","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128728_bb0305","series-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"World Health Organization","year":"2011"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:39:38Z","timestamp":1785249578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":61,"alternative-id":["S0264410X26005372"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128728","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conjugate vaccine technology enhances responses to influenza virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128728"}}